Is Nautilus Biotechnology, Inc. (NAUT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 9.8% / 30% | 41.6% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 9.8% / 33% | 41.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 12.6% / 33% | 53.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 9.8% / 33% | 41.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 12.6% / 33% | 53.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -32.3% | |
| Return on Assets (ROA) | -19.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$51M |
| Free Cash Flow | -$52M |
| Total Debt | $30M |
| Debt-to-Equity | 19.1 |
| Current Ratio | 13.3 |
| Total Assets | $191M |
Price & Trading
| Last Close | $3.78 |
| 50-Day MA | $2.49 |
| 200-Day MA | $1.52 |
| Avg Volume | 211K |
| Beta | 1.4 |
|
52-Week Range
$0.62
| |
About Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Nautilus Biotechnology, Inc. (NAUT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Nautilus Biotechnology, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Nautilus Biotechnology, Inc.'s debt ratio?
Nautilus Biotechnology, Inc.'s debt ratio is 9.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.6%.
What are Nautilus Biotechnology, Inc.'s key financial metrics?
Nautilus Biotechnology, Inc. has a market capitalization of $440M. Return on equity stands at -32.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.